BSE: 524548
SHARMA EAST INDIA HOSPITALS &
Operates a single hospital in Jaipur (marketed as 'Jaipur Hospital') providing inpatient care, surgeries and related medical services under the registered name Sharma East India Hospitals & Medical Research Ltd. For FY26, total operating income stood at ₹3,608.91 lakhs, up roughly 19.6% from ₹3,018.53 lakhs in FY25, with the H1 FY26 filing attributing the rise to an uptick in patient admissions and surgery volumes. Net profit after tax, however, was broadly flat at ₹124.27 lakhs in FY26, and the FY26 EBITDA margin was around 10.56%. The cost structure is led by other operating expenses (36.0% of revenue), followed by materials (15.0% — medical consumables and pharmacy) and employee costs (13.9% — doctors, nurses and support staff), with depreciation at 4.8% and capex at 2.2% of revenue. The H1 FY26 results flagged a swing in operating cash flow to ₹(250.65) lakhs on higher receivables and inventory build-up, and short-term borrowings rose to ₹427.31 lakhs. The business runs from one site in Jaipur under Managing Director Dr. Shailendra Kumar Sharma, and is a small-cap healthcare services provider listed on BSE. AR · MarketPing reader · 2026-08-02
Revenue streams, as the annual report describes them. Hospital and healthcare services. Small-cap, single-site hospital operator with asset-heavy infrastructure and a service-led revenue model.
Exhibit 1: Financial summary, FY22–FY26 (all audited; no estimate years)
| ₹ crore · standalone | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| Revenue | 17 | 21 | 19 | 30 | 36 |
| EBITDA (ex other income) | 2 | 3 | (2) | 4 | 4 |
| margin % | 13.2 | 15.9 | (10.1) | 12.2 | 10.1 |
| Owners' profit | 1 | 1 | 1 | 1 | 1 |
| EPS, as reported (₹) | 2.07 | 2.96 | 2.02 | 3.79 | 3.78 |
| ROE % · ROCE % | 7.1 · 13.4 | 9.2 · 15.9 | 5.9 · 15.4 | 10.0 · 15.4 | 9.1 · 14.2 |
| Debt / equity (x) | 0.45 | 0.79 | 0.45 | 0.18 | 0.53 |
| Cash from operations | 2 | 1 | (1) | 7 | (4) |
| Capex | (2) | (4) | (2) | (4) | (1) |
Exhibit 2: Quarterly performance, last 8 quarters
| ₹ crore | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 | Q1 FY27 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 9 | 8 | 6 | 9 | 9 | 10 | 7 | 11 |
| Profit before tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net profit | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (₹) | 1.03 | 0.88 | 1.12 | 0.97 | 0.97 | 0.54 | 1.31 | 0.79 |
Exhibit 3: Peers — basic industry group, by market cap
| Company | M.cap ₹ cr | P/E | P/B | EV/EBITDA | ROE % | ROCE % | Rev CAGR 5y % | EBITDA m. % |
|---|---|---|---|---|---|---|---|---|
| DR. LAL PATH LABS LTD. | 32,213 | 46.3 | 12.68 | 37.5 | 20.1 | 24.8 | 11.8 | 35.0 |
| VIJAYA DIAGNOSTIC CEN LTD | 14,838 | 79.1 | 15.50 | 41.4 | 18.1 | 16.8 | — | 46.4 |
| METROPOLIS HEALTHCARE LTD | 11,341 | 23.4 | 7.44 | 27.1 | 12.5 | 14.4 | 10.5 | 25.8 |
| THYROCARE TECH LTD | 7,871 | 28.9 | 13.43 | 28.7 | 27.8 | 33.2 | 10.9 | 33.9 |
| NEPHROCARE HEALTH SERV L | 6,301 | 65.1 | 5.64 | 24.9 | 6.9 | 8.6 | — | 25.3 |
| KRSNAA DIAGNOSTICS LTD | 1,628 | 16.7 | 1.66 | 8.3 | 10.3 | 8.4 | — | 27.7 |
| SURAKSHA DIAGNOSTIC LTD | 1,621 | 45.3 | 6.66 | 16.4 | 12.9 | 11.5 | — | 36.0 |
| 3B BLACKBIO DX LTD. | 1,170 | 19.5 | 3.53 | 13.8 | 18.1 | 22.5 | (8.9) | 52.6 |
Exhibit 4: Where the company sits in its group
| Metric | Company | Group median | Rank | Better than |
|---|---|---|---|---|
| P/E (TTM) | 22.7 | 23.4 | 12 of 25 | 54% |
| P/B | 2.0 | 2.0 | 12 of 24 | 52% |
| ROCE | 10.7 | 6.1 | 10 of 29 | 68% |
| ROE | 9.1 | 6.0 | 10 of 24 | 61% |
| Debt / Equity | 0.5 | 0.1 | 18 of 23 | 23% |
| EBITDA margin | 8.3 | 25.6 | 17 of 24 | 30% |
| Revenue growth | 13.6 | 20.8 | 17 of 25 | 33% |
| Profit growth | (18.2) | 22.0 | 18 of 25 | 29% |
| Market cap | 27 | 34 | 19 of 30 | 38% |
Exhibit 5: Filings of the last 90 days, with the measured price reaction
| Date · filing | Category | Importance | Next day % | 5-day % |
|---|---|---|---|---|
| 15 Oct 2026 · Routine RTA compliance certificate for share dematerialization | compliance | minimal | — | — |
| 1 Oct 2026 · AGM voting results: all 3 resolutions passed unanimously | board shareholder meetings | low | — | — |
| 30 Sept 2026 · 37th AGM held on Sep 30, 2026 - proceedings summary | board shareholder meetings | low | — | — |
| 29 Sept 2026 · Trading Window Closure for Q2 FY26 Results | compliance | minimal | — | — |
| 8 Sept 2026 · 37th Annual Report for FY 2025-26 submitted to BSE | results | high | — | — |
| 8 Sept 2026 · Notice of 37th AGM to be held on 30 September 2026 | board shareholder meetings | low | — | — |
| 8 Sept 2026 · Board approves 37th AGM on September 30, 2026 via video conferencing | board shareholder meetings | low | — | — |
| 13 Aug 2026 · Newspaper publication of Q1 FY27 unaudited financial results | compliance | minimal | — | — |
| 4 Aug 2026 · Board meeting on Aug 12, 2026 to approve Q1 FY27 results | results | low | — | — |
| 9 Jul 2026 · Quarterly RTA Certificate for Dematerialization Filed with BSE | compliance | minimal | — | — |
How to read this document
| Where a broker report shows | This document shows | Why |
|---|---|---|
| A rating (BUY / ADD / REDUCE / SELL) | A state: the latest filed quarter and the measured reactions | an event is a fact; a rating is an opinion that requires SEBI RA registration |
| A target price and upside | The current price and the multiples against the group | a target is a forecast; a multiple is a measurement |
| Estimate years marked E | More audited years; no estimates | MarketPing publishes no forecasts — your own model lives on the Models page |
Sources, method and disclosures
This document is a statistical summary of publicly filed information and market data, prepared by software from primary sources: SEBI results XBRL filed with BSE and NSE, LODR disclosures, shareholding patterns, exchange price data. It contains no research recommendation, no price target and no opinion on the merits of any security, and is not a research report within the meaning of the SEBI (Research Analysts) Regulations, 2014, Regulation 2(1)(w)(vii). Financial statements are as filed (consolidated where the company files consolidated results). Ratios are computed over filed lines. Where a figure is unavailable the table shows a dash rather than an estimate. The business brief is written by MarketPing's reader from the annual report and checked against it; no figure in a table was generated by a model. Nothing here constitutes investment advice, an offer or a solicitation; readers should consult a SEBI-registered adviser before acting. MarketPing is not a SEBI-registered intermediary.